Frontera Therapeutics

Clinical-stage gene therapy company developing in-house recombinant adeno-associated virus (rAAV) gene therapies targeting ophthalmic and cardiovascular diseases, with a pipeline of six candidates including treatments for X-linked retinitis pigmentosa, nAMD, DME, and inherited retinal diseases in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Leased property
• Other
• Supplier concentration
• Outsourced production (OEM / contract manufacturing)
• Capacity and utilisation
• Cash burn and runway
• Inventory level and ageing
• Investments and fair-value assets
• Adverse change after the track record
• Chapter 18A biotech
• Contractual arrangements (VIE)